Showing results (1-10 of 64) with videos related to
Sort By:
Pageof 7
Diabetes & Vascular Disease Research|July 4, 2012
Glucose perturbations and cardiovascular risk: challenges and opportunitiesLars Rydén, Linda MellbinExpert Review of Cardiovascular Therapy|October 27, 2012
Evidence for a beneficial effect of glucose-insulin-potassium in patients with acute coronary syndromes: Did the IMMEDIATE trial solve an unanswered question?Linda Mellbin, Lars RydénCurrent Vascular Pharmacology|December 25, 2012
Joint ESC/EASD guidelines on diabetes, where are we now and where should we go?Lars Rydén, Linda MellbinEuropean Journal of Preventive Cardiology|November 27, 2019
Risk factor reduction in type 2 diabetes demands a multifactorial approachLars Rydén, Giulia Ferrannini, Linda MellbinClinical Therapeutics|April 25, 2016
Clinical Implications of Cardiovascular Outcome Trials in Type 2 Diabetes: From DCCT to EMPA-REGLars Rydén, Bahira Shahim, Linda MellbinEuropean Journal of Preventive Cardiology|June 17, 2017
Diabetes: Prevalence, prognosis and management of a potent cardiovascular risk factorAnna Norhammar, Linda Mellbin, Francesco CosentinoDiabetes Technology & Therapeutics|March 10, 2010
Glucose monitoring by means of an intravenous microdialysis catheter techniqueCamilla Hage, Linda Mellbin, Lars Rydén, et al.Herz|June 24, 2008
Cardiovascular prevention in patients with diabetes and prediabetesMatteo Anselmino, Helmut Gohlke, Linda Mellbin, et al.Reviews in Cardiovascular Medicine|April 18, 2008
Early detection and integrated management of dysglycemia in cardiovascular disease: a key factor for decreasing the likelihood of future eventsMatteo Anselmino, Linda Mellbin, Märit Wallander, et al.European Journal of Preventive Cardiology|March 30, 2012
Fasting glucose, HbA1c, or oral glucose tolerance testing for the detection of glucose abnormalities in patients with acute coronary syndromesCamilla Hage, Pia Lundman, Lars Rydén, et al.Pageof 7